Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470184 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00470184 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 41 participants.
The verdict
NCT00470184, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with radiation therapy works in treating patients undergoing surgery for stage II, stage III, or stage IV esophageal cancer.
Interventions
- GENETIC gene expression analysis
- GENETIC microarray analysis
- DRUG oxaliplatin
- DRUG capecitabine
- GENETIC reverse transcriptase-polymerase chain reaction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470184
The ClinicalTrials.gov registry entry for NCT00470184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00470184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470184 about?
NCT00470184 is a clinical study titled "Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radia...
What is the current status of trial NCT00470184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00470184?
The interventions under investigation include: gene expression analysis (GENETIC), microarray analysis (GENETIC), oxaliplatin (DRUG), capecitabine (DRUG), reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT00470184?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.